Johnson & Johnson Receives Approval in China for Oral Psoriasis Treatment
Chinese regulators have granted approval for Icotyde, an oral medication developed by Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX), to treat plaque psoriasis. The drug is a once-daily pill designed as a treatment option for patients suffering from this autoimmune skin condition. The approval was issued by China’s National Medical Products Administration, marking an important regulatory milestone for the companies involved in its development. This decision could expand access to innovative therapies within one of the world's largest pharmaceutical markets and potentially boost sales for both J&J and PTGX.
Topics: Johnson & Johnson pharmaceuticals Protagonist Therapeutics regulatory approvals